Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma
Clinical Lymphoma Myeloma and Leukemia · 2024-11 · 24 (11) · 762-769
DOI: 10.1016/j.clml.2024.06.004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024-11. Verfasst von Tanvi H Patel und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR. Hauptthemen laut MEDLINE: Multiple Myeloma, Ubiquitin-Protein Ligases, Thalidomide. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 62 Literaturangaben.
Abstract (Originalsprache)
Multiple Myeloma (MM) remains a challenging hematological malignancy despite significant advancements made during the past 2 decades. Outcomes have improved by incorporating immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies into treatment algorithms that include high dose chemotherapy and autologous hematopoietic stem cell transplantation. However, many patients may eventually relapse despite these innovations. Newer therapies targeting B-Cell Maturation Antigen (BCMA) offer promise for patients with relapsed or refractory disease. BCMA-targeted therapies carry notable side effects, necessitating vigilant monitoring and proactive infection prevention measures. They can also induce considerable immunosuppression, attributed to lower levels of immunoglobulins and increased susceptibility to infections. There is still a need for alternative treatment options with different mechanisms of action that can be easily administered and have a better safety profile. In addition, pomalidomide only overcomes lenalidomide refractoriness in a subset of patients. This review aims to explore 2 next-generation cereblon E3 ligase modulators (CELMoDs), Mezigdomide (CC92480), and Iberdomide (CC-220). We will discuss the biological aspects of these agents, including their mechanisms of action, efficacy, and toxicity profile, and provide a comprehensive review of current literature. Special attention will be paid to ongoing and future clinical trials that provide insights into the potential of these novel therapies in the management of MM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR.
- Department of Hematology and Oncology, Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR. Electronic address: salhadidi@uams.edu.
Zitieren
APA
Patel, T. H., van Rhee, F., & Al Hadidi, S. (2024). Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia, 24(11), 762-769. https://doi.org/10.1016/j.clml.2024.06.004
Vancouver
Patel TH, van Rhee F, Al Hadidi S. Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. 2024;24(11):762-769. doi:10.1016/j.clml.2024.06.004
BibTeX
@article{Patel2024,
author = {Patel, Tanvi H and van Rhee, Frits and Al Hadidi, Samer},
title = {Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2024},
volume = {24},
number = {11},
pages = {762--769},
doi = {10.1016/j.clml.2024.06.004}
}
EUVIMED